10 July 2026: World first trial offers hope for patients who experience repeated IVF failures | 7News
Insights from:
Key takeaways
- A world-first clinical trial is investigating whether the immune system may play a role in repeated IVF failure and recurrent miscarriage.
- Natural killer cells are the focus of the research, which is exploring whether abnormal activity or cell numbers may affect implantation.
- A simple blood test will determine whether patients qualify for the study by identifying abnormal natural killer cell activity.
- Genea is recruiting up to 1,600 IVF patients across Australia for what is described as the largest trial of its kind worldwide.
- Dr Rose McDonnell explains that identifying abnormal natural killer cell activity before embryo transfer may provide an opportunity to modify the immune environment to facilitate implantation.
- The trial aims to provide answers for patients who have experienced repeated IVF failure or recurrent miscarriage without knowing why.
- Ongoing research continues to improve understanding of fertility and may help guide future approaches to recurrent implantation failure.
A world-first clinical trial is aiming to provide new insights for patients who have experienced repeated failed IVF attempts or recurrent miscarriage by investigating whether the immune system may play a role in unsuccessful pregnancies.
Led by Genea, the national trial is exploring whether natural killer cells, an important part of the immune system, may be associated with recurrent implantation failure and recurrent miscarriage. The study aims to better understand whether abnormal natural killer cell activity or numbers could be a contributing factor for some patients who have experienced repeated unsuccessful IVF treatment.
Featuring insights from Genea Fertility Specialist Dr Rose McDonnell, the research seeks to answer questions many patients have after multiple unsuccessful IVF cycles and provide a greater understanding of why implantation may not occur despite repeated embryo transfers.
One patient's IVF Journey
For Ria Miocevich, becoming a mother was a long and emotionally challenging journey.
Over four years, she underwent seven egg collections, 11 embryo transfers, multiple miscarriages and first-trimester pregnancy losses before welcoming her daughter, Melena.
Reflecting on her experience, Ria described the process as heartbreaking and gut-wrenching at times. Each IVF cycle brought renewed hope, while also carrying the emotional and financial demands that can accompany fertility treatment.
Despite everything she experienced, Ria says becoming a mother made the journey worthwhile.
One of the most difficult parts of her experience was not knowing why treatment had not resulted in a successful pregnancy. After years of IVF, there was still no clear explanation for the repeated unsuccessful outcomes. Her story reflects the uncertainty that many patients experience following recurrent implantation failure or recurrent miscarriage and highlights why research into possible contributing factors remains so important.
Investigating the role of the immune system
The focus of the trial is natural killer cells, which are a critical part of the immune system.
As explained by Dr Rose McDonnell, natural killer cells help attach the embryo to the womb. The study is investigating whether abnormal natural killer cell activity or numbers may play a role in recurrent implantation failure or recurrent miscarriage.
According to Dr McDonnell, 10 to 15 per cent of women are affected by recurrent implantation failure or recurrent miscarriage, highlighting the need for continued research into why some pregnancies do not progress as expected.
Rather than assuming the immune system is responsible in every case, the trial aims to investigate whether abnormal natural killer cell activity could be one factor contributing to repeated unsuccessful IVF attempts for some patients.
By exploring this relationship, researchers hope to better understand implantation and provide additional information for patients who continue to search for answers after multiple unsuccessful treatment cycles.
A World-first clinical trial led by Genea
Genea is leading the national study, which will recruit up to 1,600 IVF patients from across Australia, making it the largest trial of its kind worldwide.
The trial has already commenced in Western Australia, with Sydney set to follow.
Participation begins with a simple blood test, which is used to determine whether patients qualify for the study by identifying whether natural killer cell activity or cell numbers are abnormal.
Researchers will use this information to investigate whether identifying abnormal natural killer cell activity before embryo transfer may provide additional insight into recurrent implantation failure and recurrent miscarriage.
For patients who have experienced repeated IVF failure without understanding why, the trial represents an opportunity to investigate another possible factor before embryo transfer takes place.
Insights from Dr Rose McDonnell
Dr Rose McDonnell explains that patients like Ria may benefit from understanding whether natural killer cell activity or cell numbers are abnormal before an embryo is transferred.
According to Dr McDonnell, identifying this information ahead of embryo transfer may provide an opportunity to modify the immune environment to facilitate implantation.
The study aims to determine whether this approach could improve understanding of recurrent implantation failure and recurrent miscarriage, while contributing to ongoing fertility research.
For many patients, repeated unsuccessful treatment cycles can leave them searching for answers. By investigating the potential role of the immune system, the research hopes to provide greater insight into one possible factor involved in implantation.
Why this research matters
Repeated IVF failure and recurrent miscarriage can be physically and emotionally challenging experiences, particularly when there is no clear explanation for why pregnancies have not progressed.
This world-first clinical trial aims to better understand whether abnormal natural killer cell activity may be associated with repeated unsuccessful IVF attempts and recurrent miscarriage. By identifying this activity before embryo transfer through a simple blood test, researchers hope to provide valuable insights into implantation and reproductive outcomes.
Through Ria's personal story and Dr Rose McDonnell's expert perspective, the article highlights both the challenges many patients face during fertility treatment and the importance of ongoing research into recurrent implantation failure.
As recruitment continues across Australia, the study offers hope that further research may help answer some of the questions patients face after repeated IVF failure while contributing to future advances in fertility care.
About the authors
Dr. Rose McDonnell
Fertility Specialist MBBS FRANZCOG BSci (Med Sci) MRMed
Dr Rose McDonnell is a highly qualified obstetrician and gynaecologist with advanced expertise in laparoscopic pelvic surgery, fertility medicine, and endometri
View profile
Talk to a Fertility Concierge
Have questions about recurrent IVF failure, recurrent miscarriage or your fertility options? Our Fertility Concierge team can answer your questions, explain your options and help you connect with the right support.
